Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Gains from Sales and Divestitures (2021)

Barinthus Biotherapeutics (BRNS) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $514923.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Gains from Sales and Divestitures changed N/A year-over-year to $514923.0, compared with a TTM value of $514923.0 through Dec 2021, changed N/A, and an annual FY2021 reading of $514923.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $514923.0 for Q4 2021 at Barinthus Biotherapeutics, roughly flat from $514923.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $514923.0 in Q2 2021 and bottomed at $514923.0 in Q2 2021.